Carilex Medical (ROCO:7726) Research & Development: NT$23.1 Mil (TTM As of Dec. 2025)


ROCO:7726 Carilex Medical Inc ROCO:7726
34 GF Score
Price NT$32.40
! 5 Warning Signs
View Full Analysis

What is Carilex Medical Research & Development?

Carilex Medical ROCO:7726 -0.15% 34 Research & Development is NT$23.1 Mil as of Dec. 2025. GuruFocus rates ROCO:7726 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Carilex Medical's Research & Development for the six months ended in Dec. 2025 was NT$11.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$23.1 Mil.

Carilex Medical  (ROCO:7726) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Carilex Medical Research & Development Related Terms

Carilex Medical Research & Development Historical Data

* Premium members only.

The historical data trend for Carilex Medical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carilex Medical Research & Development Chart

Carilex Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 29.88 13.23 18.63 23.08 23.11

Carilex Medical Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.57 12.25 10.83 11.73 11.38
ROCO:7726
34GF Score
Carilex Medical Inc ROCO:7726
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carilex Medical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$23.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$23.1 Mil mean?
Carilex Medical (ROCO:7726) has a Research & Development of NT$23.1 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Carilex Medical and its competitors.
Is Carilex Medical's Research & Development too high?
Carilex Medical's current Research & Development is NT$23.1 Mil. Overall, Carilex Medical has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's Research & Development compare to ABT and SYK?
Carilex Medical's Research & Development of NT$23.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Carilex Medical and its competitors. Carilex Medical's current Research & Development is NT$23.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current Research & Development of NT$23.1 Mil. The current Research & Development is NT$23.1 Mil. Carilex Medical's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current Research & Development is NT$23.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Carilex Medical Business Description

Address No.77, Keji 1st Road, Guishan District, Taoyuan, TWN, 33383
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
34GF Score

Get the complete analysis for ROCO:7726

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.40
Price